Radiation dose measurements for staff members involved in holmium-166 preclinical trial

详细信息    查看全文

• 作者：Jacqueline Taleb ; Marc Janier ; Pauline Bonazza ; Patrick Roux ; Imen Miladi ; Cynthia Goutain-Majorel ; Claire Billotey ; David Kryza
• 关键词：Holmium 166 ; Radiation protection ; Skin dose ; Whole body dose
• 刊名：Radiation Measurements
• 出版年：November, 2013
• 年：2013
• 卷：58
• 期：Complete
• 页码：75-78
• 全文大小：218 K

文摘

Aim

Neutron-activated holmium-166 (¹⁶⁶Ho) is an excellent radionuclide for internal radiation therapy (E尾max聽=聽1.84聽MeV) with an appropriate half-life (26.8聽h), which emits photons (81聽keV, 6.2%) suitable to be detected by gamma cameras. Preparing and injecting radiopharmaceuticals containing beta/gamma emitting holmium-166 implies a risk of exceeding the upper limit for skin and hand radiation equivalent doses (500聽mSv/an). This study was aimed to estimate the whole body and finger exposure for staff responsible for dose preparation, dose dispensing, and dose injection of holmium-166 therapy.

Methods

To measure the finger dose from external exposure, all staff members wore TLD dosimeters. Personal dose equivalents Hp(10) were measured using electronic personal dosimeters (EPD MK2, Thermo Fischer Scientific) placed on the left side of the chest. During our study, staff members administered more than 40 ¹⁶⁶Ho-based therapies for preclinical trial. Appropriate radiation safety procedures and shielding were applied at each stage.

Results

In this study, the whole body doses were 2.80聽卤聽1.56聽nSv聽MBq^鈭? for one ¹⁶⁶Ho-therapy preparation/formulation, and 2.68聽卤聽1.70聽nSv聽MBq^鈭? for one intravenous injection. Maximum finger doses were 2.9聽卤聽0.2聽渭Sv聽MBq^鈭? and 2.5聽卤聽0.3聽渭Sv聽MBq^鈭? for preparation and injection, respectively (activities injected: 72聽卤聽3聽MBq).

Conclusion

Extrapolated annual doses from 300 ¹⁶⁶Ho radionuclide therapies were lower than the annual limit doses for skin and the whole body, 500聽mSv and 20聽mSv, respectively, reported in the European Directive EURATOM 96/29 when applying appropriate radiation protection standards. However, these doses have to be added to other diagnostic or therapeutic protocols, performed in preclinical facilities.